Drug Trial Radar · NCT07161037
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
26
Actual
Start
Nov 19, 2025
Primary completion
Jul 22, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Sep 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407Drug
Tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- htTKV on MRI Over TimeTime frame: Baseline up to End of Study (Week 52)
Locations
43 sites in 8 countries. Site status is shown where the registry gives one.
Alabama Kidney Research
Alabaster, Alabama
UAB Nephrology Research at CH19
Birmingham, Alabama
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
UCSF Clinical Research Center at Parnassus
San Francisco, California
Nephrology & Hypertension Associates, PC
Middlebury, Connecticut
Yale University - Yale Nephrology Clinical Research Clinic
New Haven, Connecticut
Mayo Clinic - Jacksonville
Jacksonville, Florida
Emory School of Medicine - Renal Division
Atlanta, Georgia
Renal Associates
Columbus, Georgia
UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology
Chicago, Illinois
University of Iowa Health Care Medical Center- Nephrology
Iowa City, Iowa
Clinical & Translational Science Unit (CTSU) - Nephrology
Kansas City, Kansas
University of Maryland Medical Center - General Clinical Research Center
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center - Nephrology
Boston, Massachusetts
University of Minnesota -Clinics and Surgery Center (CSC) - Endocrine Clinic
Minneapolis, Minnesota
Mayo Clinic - Rochester
Rochester, Minnesota
DaVita Kidney Care - Las Vegas
Las Vegas, Nevada
The Rogosin Kidney Center
New York, New York
General Nephrology Clinic - New York City
New York, New York
Cleveland Clinic - Main Campus
Cleveland, Ohio
Geisinger Clinic
Danville, Pennsylvania
Perelman Center for Advanced Medicine - Nephrology
Philadelphia, Pennsylvania
Nephrology Clinical Trials Center
Nashville, Tennessee
UVM Medical Center - 1 South Prospect Street
Burlington, Vermont
Swedish Center for Comprehensive Care
Seattle, Washington
Universite Catholique de Louvain - Nephrology
Brussels, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Nephrology
Leuven, Belgium
McGill University Health Centre
Montreal, Canada
Centre Hospitalier Regional Universitaire (CHRU) Brest
Brest, France
Hopital Necker Enfants Malades - Neurology
Paris, France
Hopital Bretonneau
Tours, France
Charité - Klinik für Nephrologie und Intensivmedizin der
Berlin, Germany
University Hospital Cologne (Koeln) - Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin
Cologne, Germany
UMCG - Nephrology
Groningen, Netherlands
Fundacio Puigvert
Barcelona, Spain
Hospital Fundacion Jimenez Diaz
Madrid, Spain
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom
King's College Hospital - Pulmonology
London, United Kingdom
Royal Free Hospital - Nephrology
London, United Kingdom
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.